<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prevalence of <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VAD) increases with aging of the population </plain></SENT>
<SENT sid="1" pm="."><plain>The role of <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> in the pathogenesis of AD is unclear: apoE(2) offers protection and apoE(3) is neutral, while apoE(4) promotes the development of the disease </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, several studies have confirmed the role of <z:mp ids='MP_0003674'>oxidative stress</z:mp> in the pathogenesis of AD and VAD </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="17" ids="39025">HDL</z:chebi>-associated paraoxonase is one of the antioxidative enzymes that may reduce <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidation </plain></SENT>
<SENT sid="4" pm="."><plain>In our study, we investigated the <z:chebi fb="23" ids="18059">lipid</z:chebi> parameters of the sera and the serum paraoxonase activity in patients with AD and VAD </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi> parameters were determined by an autoanalyzer in 30 AD patients, 40 VAD patients and 40 healthy, age-matched control (C) subjects </plain></SENT>
<SENT sid="6" pm="."><plain>Paraoxonase activity was measured spectrophotometrically using <z:chebi fb="0" ids="27827">paraoxon</z:chebi> as the substrate </plain></SENT>
<SENT sid="7" pm="."><plain>The phenotypic distribution of paraoxonase was determined by the dual substrate method, using <z:chebi fb="0" ids="27827">paraoxon</z:chebi> and <z:chebi fb="0" ids="8082">phenylacetate</z:chebi> as substrates </plain></SENT>
<SENT sid="8" pm="."><plain>In our results, we found that most of the patients with AD had the apoE(4) isoform, consistent with other studies </plain></SENT>
<SENT sid="9" pm="."><plain>In the VAD and AD patients we found significantly higher total-cholesterol compared to the control group (C: 4.71 +/- 0.89, VAD: 6.3 +/- 0.8, AD: 6.52 +/- 0.7 mmol/l; p &lt; 0.01) and <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> levels (C: 2.6 +/- 0.6, VAD: 3.96 +/- 0.8, AD: 3.84 +/- 0.6 mmol/l; p &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>The <z:chebi fb="17" ids="39025">HDL</z:chebi>-associated <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, paraoxonase activity did not differ significantly in the patient groups, but compared to the healthy control subjects, paraoxonase activity was significantly lower in both of the patient groups (C: 188 +/- 55 U/l; AD: 131 +/- 37, VAD: 151 +/- 50 l; p &lt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>Our results suggest that the defect in <z:chebi fb="17" ids="39025">HDL</z:chebi>-associated <z:chebi fb="11" ids="22586">antioxidant</z:chebi> capacity plays a role in the pathogenesis of <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>